Chimeric antigen receptor (CAR) T cells, an immunotherapy that has been successful in treating blood cancers, has had limited efficacy in solid tumors including in pancreatic cancer. Greg Allen, MD, […]
Prepare and Thrive Through Pancreatic Cancer Treatment
Pancreatic cancer treatment is complex and often involves a combination of chemotherapy, surgery, and a demanding recovery. At the Hirshberg Foundation’s 20th Annual Symposium, Barbara Jagels, RN, MHA, CPHQ, Executive […]
What to Expect After Pancreatic Surgery
The Whipple procedure, also called pancreaticoduodenectomy, is a major operation used to treat pancreatic cancer. The surgery involves removing parts of the pancreas in an area of the digestive system […]
Dr. Mark Girgis Named Director of the UCLA Agi Hirshberg Center for Pancreatic Diseases
The Hirshberg Foundation for Pancreatic Cancer Research is pleased to welcome Dr. Mark D. Girgis as the new Director of the UCLA Agi Hirshberg Center for Pancreatic Diseases. As Director […]
First RAS inhibitor approved by the FDA
Today daraxonrasib, an oral RAS(ON) multi-selective inhibitor from Revolution Medicines, was approved by the FDA for use by patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) or for patients […]
Healing After Loss: A New Support Group for Families Grieving Pancreatic Cancer
The journey through pancreatic cancer does not end when treatment does. For many families, the loss of a loved one marks the beginning of a new chapter filled with grief, […]